Investment ProfessionalsBB Biotech: Preliminary full-year 2024 results and dividend proposal
BB Biotech AG reports the following preliminary and unaudited figures for 2024:
Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performance amounted to +3.0% in CHF, +1.7% in EUR and -4.6% in USD for 2024 (including the dividend). Full-year 2024 net profit of CHF 76 mn, compared to a net loss of CHF 207 mn in 2023.
| Performance | Full-year 2024 | Full-year 2023 | |
|---|---|---|---|
| Currency | CHF | EUR | CHF |
| BB Biotech share price | -13.5% | -14.1% | -18.1% |
| BB Biotech NAV | +3.0% | +1.7% | -7.4% |
| Net profit/loss | +76 mn | -207 mn | |
Fourth quarter 2024: BB Biotech shares returned -2.7% in CHF and -3.5% in EUR. NAV performance for the fourth quarter was +2.7% in CHF, +2.8% in EUR and -4.3% in USD. Fourth-quarter net profit of
CHF 60 mn, compared to a net profit of CHF 109 mn in Q4 2023.
| Performance | Q4 2024 | Q4 2023 | |
|---|---|---|---|
| Currency | CHF | EUR | CHF |
| BB Biotech share price | -2.7% | -3.5% | +3.4% |
| BB Biotech NAV | +2.7% | +2.8% | +5.0% |
| Net profit | +60 mn | +109 mn | |
Premium/Discount: BB Biotech’s share price closed the year at a 15.2% discount to NAV (in CHF), a sharp contrast to the 0.9% premium recorded at the start of the year. As of January 22, the discount also amounts to 15.2%. This reflects ongoing volatility and subdued investor sentiment in the biotech sector.
| January 22, 2025 | YE 2024 | YE 2023 | |
|---|---|---|---|
| Premium (+) / Discount (-), CHF | -15.2% | -15.2% | +0.9% |
Dividend Proposal: The Board of Directors will propose a regular dividend of CHF 1.80 per share at the Annual General Meeting on March 19, 2025, reflecting a 5% yield based on the average December 2024 share price. This proposal is consistent with the dividend policy adopted in 2013 and reflects BB Biotech’s disciplined approach to balance shareholder returns with reinvestment into the long-term growth opportunities of the biotech sector.
| Dividend per share | 2025 | 2024 |
|---|---|---|
| Proposal / Paid out | CHF 1.80 | CHF 2.00 |
A review of BB Biotech’s portfolio and results for 2024 as well as the outlook for 2025 will be included in the Annual Report, to be published on February 21, 2025. The figures and information provided here are preliminary and intended as a high-level overview.
For further information:
Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00
Head Investment Management Team BB Biotech
Dr. Christian Koch
Investor Relations
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch
Media Relations
Tanja Chicherio, tch@bellevue.ch